Oral Peptide Delivery in 2026: How Icotrokinra's FDA Approval Rewrites the Rules

At a Glance

Oral bioavailability of peptide drugs stays very low even with engineering: about 0.4–1% for oral semaglutide and about 0.7% for oral octreotide. Icotrokinra does not escape this. Its oral bioavailability in rats was low. It works because it binds its receptor at picomolar concentrations, so a small absorbed fraction is enough.

The Wall That Kept Peptides in Syringes

For most of the last four decades, therapeutic peptides meant injections — subcutaneous, intravenous, or intramuscular. The reason is not a lack of trying. The gastrointestinal tract is a highly evolved barrier against macromolecules that happens to match the size range of most peptide drugs.

Three barriers do most of the damage:

Enzymatic degradation. Pepsin in the stomach and proteases in the small intestine (trypsin, chymotrypsin, brush-border peptidases) break amide bonds — the same bonds holding a peptide drug together. Enzymatic hydrolysis is one of the two main reasons oral peptides are poorly absorbed [1].

The mucus and epithelial barrier. Peptides that survive the enzyme attack must cross the mucus layer (a dense glycoprotein mesh that traps charged molecules) and then the intestinal epithelium. Tight junctions between enterocytes are selectively permeable, and most peptide drugs are too large and too polar to diffuse through the cells themselves [1].

First-pass hepatic metabolism. Peptides absorbed through the portal circulation face liver peptidases before reaching systemic circulation.

The result: oral bioavailability is very low. Even oral semaglutide, formulated with an absorption enhancer, reaches only about 0.4–1% [5]. The inter-individual variability is high, and the clinical dose required to compensate is often impractical.

The first credible breakthrough was oral semaglutide (Rybelsus, 2019). Its co-formulation with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) works because SNAC buffers the fluid around the dissolving tablet, which protects semaglutide from enzymatic breakdown, and transiently enhances absorption through the stomach wall by a transcellular route, close to the tablet surface [2]. Bioavailability is still only about 0.4–1% [5], but semaglutide’s receptor potency is high enough to generate clinical effect at that level with a 14 mg daily tablet.

The oral delivery problem was not solved by Rybelsus; it was circumvented at one very specific step. That distinction matters, because icotrokinra’s approach is fundamentally different.

Icotrokinra: Rethinking from the Molecule Up

Icotrokinra (brand name Icotyde; developed by Johnson & Johnson with Protagonist Therapeutics) changed the design philosophy. Its chemists worked mainly on the molecule itself and made it bind its target so tightly that the small fraction absorbed from a tablet is enough [7]. The label names no dedicated permeation enhancer. The tablet’s film coating does contain glyceryl monocaprylocaprate, a medium-chain glyceride, and the label does not state its function [12].

Icotrokinra is a 1,898 Da macrocyclic peptide. Its ring is closed by a sulfur bridge between two modified valine residues, its ends are chemically capped, and several of its building blocks are non-natural amino acids. It binds the IL-23 receptor with picomolar affinity. In rats its oral bioavailability was still low, but oral doses blocked IL-23 signalling in the blood of rats and of healthy volunteers [7].

Its biological target is the IL-23 receptor, which sits at the apex of the Th17 inflammatory axis implicated in psoriasis, psoriatic arthritis and inflammatory bowel disease. Injectable IL-23 biologics (risankizumab, guselkumab, tildrakizumab) have been the standard of care for plaque psoriasis for years. The key question was whether a macrocyclic oral molecule could achieve comparable receptor engagement at an orally absorbable dose.

The FDA approved icotrokinra (Icotyde) on 17 March 2026 [12] for adults and adolescents aged 12 and older (≥40 kg) with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The phase 3 ICONIC program behind it comprised four trials (ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1 and 2) with 2,500 randomised participants.

What the Phase 3 Data Show

The ICONIC-ADVANCE 1 and 2 trials compared once-daily oral icotrokinra 200 mg against placebo and the oral TYK2 inhibitor deucravacitinib (Sotyktu) in adults with moderate-to-severe plaque psoriasis. Results were published in The Lancet in September 2025 [3].

At week 16:

• IGA 0/1 response (clear or almost clear skin): 68% with icotrokinra vs. 11% with placebo in ADVANCE 1; 70% vs. 9% in ADVANCE 2
• PASI 90 (90% skin clearance): 55% with icotrokinra vs. 30% with deucravacitinib and 4% with placebo in ADVANCE 1; 58% vs. 34% and 1% in ADVANCE 2 [12]. The comparison with deucravacitinib was a secondary endpoint.
• Safety: Adverse event rates through week 16 were 48% with icotrokinra vs. 57% with placebo; through week 24 they were 57% with icotrokinra vs. 65% with deucravacitinib.

The separate ICONIC-TOTAL trial (311 participants) reported clear or almost-clear scalp in 66% vs. 11% on placebo and clear or almost-clear genitals in 77% vs. 21% at week 16 [8]. Hand and foot psoriasis did not differ significantly from placebo (42% vs. 26%). None of these trials compared icotrokinra with an injectable biologic.

The trials were funded by Johnson & Johnson. Independent systematic reviews and meta-analyses of these trials were published in 2026 [11].

Three Technologies Enabling the Shift

Three technologies are driving oral peptide development. Icotrokinra relies on the first; oral semaglutide on the third:

Macrocyclization and Conformational Rigidity

Cyclizing a peptide locks it in a preferred three-dimensional conformation, reducing the degrees of freedom that endoproteases require for substrate recognition. The classic example in medicine is cyclosporine, an oral cyclic peptide immunosuppressant used for decades. What is new with icotrokinra is applying this principle to a selective IL-23 receptor antagonist, a pathway no oral drug had selectively targeted before [7].

D-Amino Acid Substitution

Replacing L-amino acids at cleavage sites with their D-enantiomers is a general way to slow breakdown by proteases, which are stereospecific. Icotrokinra does not use it: all of its chiral amino acids are in the natural L-form [7].

SNAC and Gastric Absorption (Parallel Platform)

For GLP-1 analogues, SNAC is the enhancer used in the approved tablet. It works at the stomach, not the intestine — the semaglutide tablet dissolves in gastric fluid, SNAC locally elevates pH, and semaglutide is absorbed transcellularly through the gastric mucosa [2]. In the Novo Nordisk studies it showed no evidence of an effect on tight junctions [2]. A 2023 review covers SNAC’s chemistry, toxicity and mechanism of action [4].

Implications for Integrative and Peptide Medicine

Most peptides used in integrative and longevity medicine today, such as BPC-157, TB-500, GHK-Cu and thymosin alpha-1, are given by injection. Among the GLP-1 analogues, semaglutide also has an approved oral form. Oral BPC-157 formulations exist and are used. In my practice I use the oral route for gut problems and injection for systemic use. The evidence for gut effects comes from animal studies; there are no controlled human trials of oral BPC-157 [10] [see: BPC-157 Oral vs Injection: Which Route Delivers Better Results?].

The icotrokinra story matters for this field in two specific ways:

It proves the engineering concept. Peptide drugs do not inevitably require injection. For molecules in the 1–5 kDa range with well-defined receptor targets, a macrocyclic design with very high receptor potency can produce clinical effect despite low oral bioavailability. As these technologies diffuse through drug development, the number of verified oral peptide options will grow over the next decade.

It sets the evidence bar. Icotrokinra went through four phase 3 trials and rigorous head-to-head comparison before approval. The peptide compounds used in integrative clinics operate in an entirely different regulatory and evidentiary environment. The lesson from icotrokinra is not that any peptide can now be put in a capsule — it is that credible oral delivery needs a molecule or a formulation built for the gut, measured absorption in humans, and clinical outcome data. A capsule formulation of an unmodified peptide does not share icotrokinra’s oral pharmacology.

For the integrative medicine practitioner, nothing about this approval changes clinical protocol today. Injection-route peptide administration remains the evidence-supported standard for systemic delivery. The oral peptides discussed here with an approved, label-defined dose are oral semaglutide (Rybelsus) and oral octreotide (Mycapssa) [6], cyclosporine (Neoral) [14] and icotrokinra (Icotyde, 200 mg once daily [12]). Where unapproved peptides are used orally, it is a practice choice, not a trial-backed one: oral BPC-157 for GI-tract disease (animal data only [10]) and oral DSIP for sleep (oral absorption shown only in newborn rats [13]).

Related Articles

• BPC-157 Oral vs Injection: Which Route Delivers Better Results?
• Peptide Therapy: Benefits, Safety and How It Works
• FDA 2026 Category 1 Peptide Compounding: What It Means for Patients
• Thymosin Alpha-1: Complete Clinical Guide
• GLP-1 Peptides in Geroscience: What the Longevity Research Shows